Erratum: Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis (Cell Stem Cell (2020) 27(1) (147–157.e7), (S1934590920301570), (10.1016/j.stem.2020.04.018))

(Cell Stem Cell 27, 147–157.e1–e7; July 2, 2020) In the original online version of our manuscript, Figure 1H was printed incorrectly due to a technical issue. The figure has now been corrected in both the print and online versions of our manuscript and is also reproduced below. The corrections to Figure 1H do not change the scientific conclusions of the article in any way. Additionally, one of our contributing authors was mistakenly listed as “Meissner Torsten” (with first name and surname flipped), but Torsten Meissner now appears correctly in the author list. We apologize for the confusion.Figure 1AADAC Is Upregulated in dVSMCs Derived from T2DM Patients without CVD, originalView Large Image Figure ViewerDownload Hi-res image Download (PPT) Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against AtherosclerosisToyohara et al.Cell Stem CellMay 14, 2020In BriefWhy some patients with type 2 diabetes are protected against cardiovascular disease (CVD) has not been clarified. Toyohara et al. reveal that in patients protected from CVD, arylacetamide deacetylase (AADAC) is elevated in vascular smooth muscle cells (VSMCs). AADAC alters lipid metabolism and cellular processes in VSMCs and ameliorates CVD. Full-Text PDF Open Archive